Quick Answer
4D Molecular Therapeutics, Inc. reported Net Income of -$140.11 million for fiscal year 2025.
4D Molecular Therapeutics, Inc. Net Income — Annual History
| Fiscal Year | Net Income | YoY Change |
|---|---|---|
| 2025 | -$140.11M | +12.9% |
| 2024 | -$160.87M | -59.5% |
| 2023 | -$100.84M | +6.2% |
| 2022 | -$107.49M | -50.7% |
| 2021 | -$71.32M | -25.8% |
| 2020 | -$56.69M | -15.0% |
| 2019 | -$49.31M | — |
Quarterly Net Income
| Quarter Ending | Net Income | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$56.88M | -29.7% | -4.1% |
| June 30, 2025 | -$54.66M | -56.4% | -13.9% |
| March 31, 2025 | -$47.97M | -48.1% | -9.4% |
| September 30, 2024 | -$43.84M | -327.5% | -25.4% |
| June 30, 2024 | -$34.95M | -18.0% | -7.9% |
| March 31, 2024 | -$32.40M | -13.0% | -215.9% |
| September 30, 2023 | -$10.26M | +60.1% | +65.4% |
| June 30, 2023 | -$29.62M | -5.4% | -3.3% |
- 4D Molecular Therapeutics, Inc. showed an increase of +12.9% in Net Income compared to the prior fiscal year.
- Over the 2019–2025 period, 4D Molecular Therapeutics, Inc.’s net income has declined by 184.2% (from -$49.31 million to -$140.11 million).
- The most recent figure is from 4D Molecular Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 18, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: